Company intelligence / Profile preview

Mapi Pharma

Ownership: Private
Employees: ~200
Development stage: Phase 3

Overview

Mapi Pharma has completed pivotal Phase III trials for its lead product GA Depot—a once-monthly long acting glatiramer acetate injection for relapsing multiple sclerosis. The NDA was accepted by the FDA with a PDUFA date of March 2024. Clinical data show improved safety and tolerability compared to existing therapies. Other programs are in mid-stage development targeting neurological and metabolic diseases.

Therapeutic areas: PsychiatryNeurologyMetabolic Disorders
Modalities: Small molecules (complex APIs)Depot injectable formulations (long acting injectables)
Industry: Biotech

Drug pipeline

4 assets

Dulaglutide Depot

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Viatris – exclusive license to commercialize GA Depot for relapsing forms of multiple sclerosis in key markets.

Beyond the preview

Go deeper on Mapi Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mapi Pharma.

Explore the full profile